X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (70) 70
oncology (64) 64
index medicus (59) 59
child (50) 50
female (48) 48
pediatrics (47) 47
adolescent (46) 46
male (45) 45
child, preschool (43) 43
infant (37) 37
children (34) 34
cancer (33) 33
chemotherapy (31) 31
hematology (30) 30
neuroblastoma (30) 30
article (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
health aspects (16) 16
infant, newborn (15) 15
patients (15) 15
retrospective studies (15) 15
acute myeloid leukemia (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
care and treatment (12) 12
leukemia (12) 12
mortality (12) 12
tumors (12) 12
acute myeloid-leukemia (11) 11
disease-free survival (11) 11
prognosis (11) 11
adult (10) 10
clinical trials (10) 10
follow-up studies (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
therapy (10) 10
treatment outcome (10) 10
united-states (10) 10
analysis (9) 9
diagnosis (9) 9
high-risk neuroblastoma (9) 9
medical informatics (9) 9
neuroblastoma - therapy (9) 9
stem cells (9) 9
young adult (9) 9
cohort studies (8) 8
epidemiology (8) 8
n-myc (8) 8
neoplasms - drug therapy (8) 8
neuroblastoma - drug therapy (8) 8
neuroblastoma - genetics (8) 8
research (8) 8
risk (8) 8
risk factors (8) 8
transplantation (8) 8
camptothecin - analogs & derivatives (7) 7
databases, factual (7) 7
hematology, oncology and palliative medicine (7) 7
maximum tolerated dose (7) 7
neuroblastoma - pathology (7) 7
solid tumors (7) 7
united states (7) 7
usage (7) 7
abridged index medicus (6) 6
acute lymphoblastic-leukemia (6) 6
animals (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
camptothecin - administration & dosage (6) 6
expression (6) 6
hospitals (6) 6
medical research (6) 6
neuroblastoma - mortality (6) 6
neutropenia (6) 6
oncology-group (6) 6
original reports (6) 6
radiation-therapy (6) 6
relapse (6) 6
stem-cell transplantation (6) 6
survival (6) 6
antineoplastic agents - adverse effects (5) 5
benzoquinones (5) 5
childrens oncology group (5) 5
classification (5) 5
cohort (5) 5
dacarbazine - administration & dosage (5) 5
dacarbazine - analogs & derivatives (5) 5
dose-response relationship, drug (5) 5
hospitals, pediatric (5) 5
hospitals, pediatric - statistics & numerical data (5) 5
hsp90 heat-shock proteins - antagonists & inhibitors (5) 5
hsp90 heat-shock proteins - metabolism (5) 5
immunotherapy (5) 5
lactams, macrocyclic (5) 5
medical colleges (5) 5
molecular chaperone (5) 5
neoplasm recurrence, local - drug therapy (5) 5
neuroblastoma - diagnostic imaging (5) 5
pediatric (5) 5
pediatric-oncology-group (5) 5
pediatric-patients (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 12/2014, Volume 11, Issue 12, pp. 704 - 713
Journal Article
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 08/2019, Volume 322, Issue 8, pp. 729 - 731
The article discusses the findings of a study to evaluate whether tandem autologous transplant is effective in improving event-free survival (EFS) as compared... 
MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | THERAPY | DISEASE | OPEN-LABEL | HIGH-DOSE CHEMOTHERAPY | PROGNOSTIC-SIGNIFICANCE | INDUCTION | STAGE 4 NEUROBLASTOMA | CHILDREN | Care and treatment | Usage | Transplantation | Neuroblastoma | Risk factors | Stem cells | Risk groups | Precision medicine
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 946 - 957
Summary Background Outcomes for children with relapsed and refractory neuroblastoma are dismal. The combination of irinotecan and temozolomide has activity in... 
Hematology, Oncology and Palliative Medicine | Dacarbazine - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | N-Myc Proto-Oncogene Protein - genetics | Neoplasm Recurrence, Local - drug therapy | Infant | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Pain - chemically induced | Fever - chemically induced | Infection - chemically induced | Ganglioneuroblastoma - diagnostic imaging | Neoplasm Recurrence, Local - diagnostic imaging | Hypokalemia - chemically induced | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Ganglioneuroblastoma - drug therapy | Neutropenia - chemically induced | Child | Sirolimus - adverse effects | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Dacarbazine - administration & dosage | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Sirolimus - analogs & derivatives | Ganglioneuroblastoma - genetics | Neuroblastoma - genetics | Anemia - chemically induced | Neuroblastoma - diagnostic imaging | Survival Rate | Thrombocytopenia - chemically induced | Disease-Free Survival | Retreatment | Sirolimus - administration & dosage | Gene Amplification | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Adolescent | Neoplasm Recurrence, Local - genetics | Hypoxia - chemically induced | Medical colleges | Stem cells | Neuroblastoma
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2007, Volume 25, Issue 34, pp. 5410 - 5417
Journal Article
Current opinion in pediatrics, ISSN 1040-8703, 02/2019, Volume 31, Issue 1, pp. 14 - 20
Purpose of review Our understanding of the biologic basis of neuroblastoma, the genetic heterogeneity of this malignancy and the role of host factors has... 
targeted therapy | NATURAL-KILLER-CELLS | risk classification | neuroblastoma | predisposition | OPEN-LABEL | CHEMOTHERAPY | RADIATION-THERAPY | CHILDREN | ANTI-GD2 MONOCLONAL-ANTIBODY | COPY-NUMBER | immunotherapy | PEDIATRICS | LOCAL-CONTROL | HIGH-RISK NEUROBLASTOMA | SEQUENCING REVEALS | Care and treatment | Forecasts and trends | Neuroblastoma | Risk factors | Methods | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 12/2017, Volume 123, Issue 24, pp. 4914 - 4923
BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used an objective “response” of measureable disease (Response Evaluation... 
prognostic | historical standard | endpoints | phase 2 design | International Neuroblastoma Response Criteria (INRC) | Response Evaluation Criteria In Solid Tumors (RECIST) | SYSTEM | DIAGNOSIS | PROGNOSIS | RISK GROUP | RELAPSE | PATHOLOGY CLASSIFICATION | INTERNATIONAL CRITERIA | ONCOLOGY | STRATIFICATION | AGE | Follow-Up Studies | United States | Humans | Child, Preschool | Antibodies, Monoclonal - therapeutic use | Infant | Male | Response Evaluation Criteria in Solid Tumors | Neuroblastoma - mortality | Neuroblastoma - therapy | Neoplasm Recurrence, Local - mortality | Cause of Death | Neoplasm Recurrence, Local - pathology | Female | Child | Neuroblastoma - pathology | Medical Oncology - methods | Risk Assessment | Neoplasm Recurrence, Local - therapy | Treatment Outcome | Combined Modality Therapy | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Usage | Oncology | Development and progression | Transplantation | Research | Neuroblastoma | Children | Health aspects | Hematopoietic stem cells | Therapy | Clinical trials | Stem cell transplantation | Standard error | Bone tumors | Design | Historical account | Bone marrow | Risk groups | Benchmarks | Patients | Survival | Hemopoiesis | Children & youth | Heterozygosity | Studies | Loss of heterozygosity | Stem cells | Bone | Solid tumors | Tumors | Cancer
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 01/2020, Volume 67, Issue 1, p. n/a
Background GD2 is a ganglioside that is ubiquitously expressed in the plasma membrane of neuroblastoma and is shed into the circulation. Procedure GD2 was... 
neuroblastoma | biomarker | ganglioside | Biomarkers | Mass spectroscopy | Risk | Liquid chromatography | Diagnostic systems | Neuroblastoma | Children | Diagnosis | Mass spectrometry | Fatty acids | Tumors
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4224 - 4235
Journal Article